Literature DB >> 21862249

OMICS-strategies and methods in the fight against doping.

Christian Reichel1.   

Abstract

During the past decade OMICS-methods not only continued to have their impact on research strategies in life sciences and in particular molecular biology, but also started to be used for anti-doping control purposes. Research activities were mainly reasoned by the fact that several substances and methods, which were prohibited by the World Anti-Doping Agency (WADA), were or still are difficult to detect by direct methods. Transcriptomics, proteomics, and metabolomics in theory offer ideal platforms for the discovery of biomarkers for the indirect detection of the abuse of these substances and methods. Traditionally, the main focus of transcriptomics and proteomics projects has been on the prolonged detection of the misuse of human growth hormone (hGH), recombinant erythropoietin (rhEpo), and autologous blood transfusion. An additional benefit of the indirect or marker approach would also be that similarly acting substances might then be detected by a single method, without being forced to develop new direct detection methods for new but comparable prohibited substances (as has been the case, e.g. for the various forms of Epo analogs and biosimilars). While several non-OMICS-derived parameters for the indirect detection of doping are currently in use, for example the blood parameters of the hematological module of the athlete's biological passport, the outcome of most non-targeted OMICS-projects led to no direct application in routine doping control so far. The main reason is the inherent complexity of human transcriptomes, proteomes, and metabolomes and their inter-individual variability. The article reviews previous and recent research projects and their results and discusses future strategies for a more efficient application of OMICS-methods in doping control. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862249     DOI: 10.1016/j.forsciint.2011.07.031

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  9 in total

Review 1.  Hormones as doping in sports.

Authors:  Leonidas H Duntas; Vera Popovic
Journal:  Endocrine       Date:  2012-09-19       Impact factor: 3.633

2.  Changes in hemoglobin profile reflect autologous blood transfusion misuse in sports.

Authors:  Nicola Lamberti; Alessia Finotti; Jessica Gasparello; Ilaria Lampronti; Christel Zambon; Lucia Carmela Cosenza; Enrica Fabbri; Nicoletta Bianchi; Francesca Dalla Corte; Maurizio Govoni; Roberto Reverberi; Roberto Gambari; Fabio Manfredini
Journal:  Intern Emerg Med       Date:  2018-03-23       Impact factor: 3.397

3.  Metabolomic signatures in elite cyclists: differential characterization of a seeming normal endocrine status regarding three serum hormones.

Authors:  Boris Labrador; François-Xavier Lejeune; Alain Paris; Cécile Canlet; Jérôme Molina; Michel Guinot; Armand Mégret; Michel Rieu; Jean-Christophe Thalabard; Yves Le Bouc
Journal:  Metabolomics       Date:  2021-07-06       Impact factor: 4.290

4.  Application of Q-TOF-MS based metabonomics techniques to analyze the plasma metabolic profile changes on rats following death due to acute intoxication of phorate.

Authors:  Zhiwen Wei; Zuxin Dong; Juan Jia; Xinhua Liang; Tao Wang; Meng Hu; Shanlin Fu; Keming Yun
Journal:  Int J Legal Med       Date:  2021-05-13       Impact factor: 2.686

5.  Time for change: a roadmap to guide the implementation of the World Anti-Doping Code 2015.

Authors:  Jiri Dvorak; Norbert Baume; Francesco Botré; Julian Broséus; Richard Budgett; Walter O Frey; Hans Geyer; Peter Rex Harcourt; Dave Ho; David Howman; Victor Isola; Carsten Lundby; François Marclay; Annie Peytavin; Andrew Pipe; Yannis P Pitsiladis; Christian Reichel; Neil Robinson; Grigory Rodchenkov; Martial Saugy; Souheil Sayegh; Jordi Segura; Mario Thevis; Alan Vernec; Marjolaine Viret; Marc Vouillamoz; Mario Zorzoli
Journal:  Br J Sports Med       Date:  2014-04-24       Impact factor: 13.800

6.  Recombinant erythropoietin in humans has a prolonged effect on circulating erythropoietin isoform distribution.

Authors:  Niels Jacob Aachmann-Andersen; Søren Just Christensen; Kristian Lisbjerg; Peter Oturai; Anne-Kristine Meinild-Lundby; Niels-Henrik Holstein-Rathlou; Carsten Lundby; Niels Vidiendal Olsen
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

7.  Serum proteomic changes after randomized prolonged erythropoietin treatment and/or endurance training: detection of novel biomarkers.

Authors:  Britt Christensen; Maja Ludvigsen; Birgitte Nellemann; John J Kopchick; Bent Honoré; Jens Otto L Jørgensen
Journal:  PLoS One       Date:  2015-02-13       Impact factor: 3.240

8.  Validation of whole-blood transcriptome signature during microdose recombinant human erythropoietin (rHuEpo) administration.

Authors:  Guan Wang; Jérôme Durussel; Jonathan Shurlock; Martin Mooses; Noriyuki Fuku; Georgie Bruinvels; Charles Pedlar; Richard Burden; Andrew Murray; Brendan Yee; Anne Keenan; John D McClure; Pierre-Edouard Sottas; Yannis P Pitsiladis
Journal:  BMC Genomics       Date:  2017-11-14       Impact factor: 3.969

9.  Fighting Doping in Elite Sports: Blood for All Tests!

Authors:  Raphael Faiss; Jonas Saugy; Martial Saugy
Journal:  Front Sports Act Living       Date:  2019-09-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.